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Long-Term Outcomes in Dogs With
Sinonasal Aspergillosis Treated With
Intranasal Infusions of Enilconazole
Long-term outcomes (mean 38±17 months) were evaluated in 27 dogs with sinonasal
aspergillosis after successful medical treatment using intranasal infusions of 1% or 2% enil-
conazole (1%, n=15; 2%, n=12). Long-term outcomes with both treatment protocols were
good, with half of the dogs being asymptomatic throughout the follow-up period. The remain-
ing dogs showed mild clinical signs compatible with chronic rhinitis/sinusitis. These clinical
signs were interpreted as chronic lymphoplasmacytic rhinitis/sinusitis and episodes of bacteri-
al rather than fungal infection. Three dogs had confirmed reinfection or relapse 2 to 36






Canine nasal aspergillosis is a relatively common disease affecting
between 12% and 34% of dogs presented for chronic sinonasal signs.1,2
Aspergillus (A.) fumigatus is the most common etiological agent, but
other subspecies such as A. niger may also be involved.3 Nasal
aspergillosis can cause severe destruction of the nasal mucosa and under-
lying turbinates.4 Clinical signs include chronic, profuse, mucopurulent
to hemorrhagic nasal discharge; nasal pain; increased airflow through the
nostril on the affected side; and ulceration, hyperkeratosis, and discol-
oration of the rhinarium.4 Severely affected dogs may also show signs of
systemic illness, such as depression and anorexia.4
Systemic treatment with oral antimycotic agents such as thiabenda-
zole, ketoconazole, itraconazole, or fluconazole is costly and requires
prolonged administration.4 Efficacy has been reported as 40% to 50% for
thiabendazole and ketoconazole and 60% to 70% for fluconazole and
itraconazole.5-8 Topical treatment with clotrimazole or enilconazole has
been associated with higher success rates and has improved the manage-
ment of this previously intractable condition.9,10 Surgical implantation of
infusion tubes and irrigation of the nasal cavities and frontal sinuses
twice daily for 7 to 14 days with topical antifungal agents have been the
standard treatment for many years.9 More recently it has been shown that
minimally invasive techniques using nonsurgically placed tubes provide
better distribution of the drugs into the sinuses, are equally effective, and
are associated with fewer complications.10-12
Several studies have evaluated different noninvasive infusion tech-
niques for their ability to establish a cure; however, only a few studies
have evaluated the long-term outcomes in dogs after confirmed resolu-
tion of the infection.10,13-17 The aims of the present study were to evalu-
ate and compare the long-term outcomes in dogs with sinonasal
aspergillosis after successful medical treatment using topical administra-
tion of enilconazole by two noninvasive infusion techniques.
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Materials and Methods
Medical records of dogs presented for investigation of
chronic nasal disease from January 1998 through May 2003
were reviewed. Dogs were included in the study if the fol-
lowing criteria were fulfilled: availability of a complete
medical record; confirmed diagnosis of sinonasal
aspergillosis based on clinical signs, radiography, or com-
puted tomography (CT); direct visualization of fungal
plaques on rhinoscopy; histopathology and fungal culturea
of nasal biopsies compatible with aspergillosis; confirmed
resolution of infection after medical treatment by follow-up
rhinoscopy, culture, and histopathology; and availability of
telephone follow-up information. Twenty-seven dogs met
the inclusion criteria. Twenty-one of these dogs had partici-
pated in a clinical study comparing the effectiveness of two
noninvasive infusion techniques using enilconazole.16 Of
the 27 dogs, 15 were treated with 1% enilconazole emul-
sionb infused via blindly placed intranasal catheters (Group
A). Twelve dogs were treated with a 2% emulsion of enil-
conazole infused through catheters endoscopically placed
into the frontal sinus (Group B). In all cases, bilateral treat-
ment was performed regardless of whether the disease was
unilateral or bilateral. Age, breed, sex, and weight of each
dog were recorded, as well as the side(s) affected.
The two treatment protocols are described in detail else-
where.16 Briefly, after meticulous debridement of the fungal
plaques and placement of the intranasal or intrasinusoidal
catheters, the dogs were positioned in dorsal recumbency
with the hard palate parallel to the table. A Foley catheterc
(20-French, 30-cc balloon) was introduced per os (PO) into
the nasopharynx. The balloon was inflated and placed at the
junction of the hard and soft palate. The pharynx was
packed with pre-counted laparotomy sponges to absorb
infusate that might leak around the balloon. The nostrils
were occluded with Foley cathetersc (12-French, 5-cc bal-
loon). Syringe pumps were used to infuse a total of 120 to
150 mL of the enilconazole emulsion into both nasal cavi-
ties over a 1-hour period. During this time, the dog’s head
was rotated longitudinally left and right for 3 minutes every
15 minutes to allow better distribution of the infusate. At the
end of the treatment, the head of the dog was tilted down-
ward, and all catheters and sponges were removed to allow
the infusate to drain from the nostrils. At induction of the
anesthesia, antimicrobial treatment was started with cefa-
zolind (20 mg/kg intravenously) and was continued with
cephalexine (20 mg/kg PO q 8 hours) for 5 days. The dogs
were reevaluated rhinoscopically every 3 to 4 weeks, and
the intranasal infusions were repeated for up to three times
until all infection had resolved. A cure was established if
there was resolution of clinical signs, absence of fungal
plaques on follow-up rhinoscopy, and a negative fungal cul-
ture (n=24). In three cases, resolution of sinonasal
aspergillosis was based only on the absence of clinical
signs, because the owners declined reevaluation and repeat-
ed rhinoscopy.
The owners of the 27 dogs were contacted via telephone
in February and March of 2004 and asked to complete a
questionnaire about the long-term treatment outcome. The
questionnaire included questions about whether the animal
was still alive and, if not, the cause of its death or euthana-
sia; the general condition of the animal; and the presence or
absence of clinical signs of nasal disease. If clinical signs
were present, the owners were asked to describe their sever-
ity and frequency. Nasal discharge was classified as serous
if described as watery; mucoid if described as white; and
mucopurulent if described as yellow or green. Other clinical
signs such as sneezing, stertor, or abnormalities of the nares
(e.g., hyperkeratosis, discoloration) were also recorded. The
owners were also asked to report additional treatments.
After completion of the survey, the dogs were classified as
having very mild (i.e., occasional sneezing, serous dis-
charge), mild (i.e., serous to mild mucopurulent discharge,
sneezing <4 times per day, mild changes to nares), moder-
ate (i.e., mucopurulent discharge, sneezing >4 times per
day, stertor, moderate abnormalities of nares), or severe
(i.e., severe mucopurulent discharge, sneezing >10 times
per day, stertor, severe abnormalities of nares, nasal pain,
affection of general condition) clinical signs. Frequencies of
clinical signs were compared in both treatment groups by
means of chi-square tests. A P value <0.05 was considered
statistically significant.
Results
Among the 27 dogs, 14 breeds were represented. The most
frequent breeds were the golden retriever (n=7), Labrador
retriever (n=3), German shepherd dog (n=3), rottweiler
(n=2), and bull terrier (n=2). Other breeds having one affect-
ed dog were the Afghan hound, dachshund, Groenendael,
Pyrenean sheepdog, basset hound, Newfoundland,
Hovawart, Great Dane, and German shorthaired pointer. One
dog was a mixed-breed dog. Eleven dogs were females (four
spayed), and 16 were intact males. Age at the time of the
diagnosis ranged from 1 to 10 years (median 5.0±2.7 years,
mean 5.1±2.5 years). Age at the time of final follow-up
ranged from 1.7 to 14 years (median 8.8±3.2 years, mean
8.5±3.2 years). Body weight ranged between 5.7 and 53 kg
(median 31.5±11.4 kg, mean 33.2±11.4 kg). Seventeen dogs
had left unilateral disease, four dogs had right unilateral dis-
ease, and six dogs had bilateral disease at the time of initial
presentation. Fourteen dogs required one course of therapy
(n=7 Group A; n=7 Group B), eight dogs had two courses
(n=4 Group A; n=4 Group B), and five dogs required three
courses (n=4 Group A; n=1 Group B) of topical treatments
to effect a cure. The figure is a rhinoscopic image of the
nasal cavity of a dog at the time a cure was established.
Follow-up periods ranged from 5 to 64 months (median
39.0±17.3 months; mean 38.6±17.3 months). Of the 27
dogs, 20 were still alive in February/March of 2004. Five
dogs were euthanized for unrelated diseases, namely, chron-
ic diarrhea (n=1), congestive heart failure (n=1), chronic
dermatitis (n=1), mammary tumors (n=1), and a bone tumor
(n=1). Two dogs died suddenly without a diagnosis. None of
the dogs died or were euthanized for nasal-related disorders.
One dog in Group A and two dogs in Group B had
rhinoscopically confirmed recurrence of sinonasal
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aspergillosis at 23 months, 36 months, and 2 months
respectively. The three dogs were asymptomatic until
relapse. When relapse was confirmed, the first dog was
treated with ketoconazolef (10 mg/kg PO q 12 hours for 6
weeks) and local thiamphenicol/acetylcysteine nasal
dropsg (q 6 hours for 10 days) with good response, and
this dog remained asymptomatic for another 28 months.
In the second dog, sinonasal flush using 2% enilconazole
was repeated, and itraconazoleh (5 mg/kg PO q 12 hours)
was given for several weeks. The dog improved, but mild
clinical signs persisted. On relapse, the third dog was
treated with several weeks of itraconazole (5 mg/kg PO q
12 hours), but moderate nasal signs persisted.
Eight of 15 dogs in Group A and five of 12 dogs in Group
B (total of 13 dogs) were asymptomatic throughout the
whole follow-up period. The remaining 14 dogs (n=7 Group
A; n=7 Group B) had persistent clinical signs of nasal dis-
ease. The Table summarizes the nasal signs that occurred
within the different treatment groups. Nasal signs were
episodic in five dogs (n=3 Group A; n=2 Group B) and con-
tinuous in nine dogs (n=4 Group A; n=5 Group B). The fre-
quency of clinical signs was not significantly different
between groups. Nasal signs were very mild in three dogs,
mild in seven dogs, and moderate in four dogs. None of the
dogs had severe signs. There was no statistical difference in
the severity of clinical signs between the two treatment
groups. No changes in the general condition of the dogs
occurred in either group.
The most common clinical signs in symptomatic dogs
were mucopurulent nasal discharge and sneezing. Three
dogs in Group B sneezed a few times in the morning, and
after they had expelled some plugs of mucopurulent materi-
al, no sneezing or nasal discharge occurred throughout the
rest of the day.
Stertor was a relatively uncommon sign, but abnormali-
ties of the nares were reported in more than half of the
symptomatic dogs. Only a few dogs (n=6) were considered
by the owners to need any treatment. Treatments were pre-
scribed by the referring veterinarians in most cases. One
dog in Group A received methylprednisolonei (0.5 mg/kg
PO q 24 hours) continuously to control nasal signs. Two
other dogs in Group A were treated one to three times with
oral ketoconazole or itraconazole and saline nasal drops.
Both dogs appeared to respond and were only very mildly
and episodically symptomatic. One dog in Group A and two
dogs in Group B occasionally received topical treatment
with thiamphenicol/acetylcysteine nasal drops, but they still
had mild nasal clinical signs.
Discussion
Although not compared with a standard hospital-based con-
trol population, the signalments of the dogs included in this
study were similar to previous reports in that canine nasal
aspergillosis mainly affected young to middle-aged dogs of
mesocephalic or dolichocephalic breeds.4 Initial comparison
of the two topical treatment protocols described in this report
suggested that the latter technique required fewer infusions
to reach a cure.16 The results of the current study, however,
did not reveal any statistically significant differences in the
long-term outcomes between the two treatment groups.
In two studies that evaluated the long-term outcomes in
dogs after topical treatment with either clotrimazole or enil-
conazole, a single episode of nasal discharge occurred in
seven of 57 and in five of 31 dogs, respectively.10,17 No per-
manent nasal signs were reported. The follow-up periods in
these two studies ranged from five to 61 months.10,17 In
contrast to these findings, about half of the dogs in the pres-
ent study showed mild nasal signs after successful treatment
of nasal aspergillosis. The general condition was not affect-
ed, however. The persistent nasal signs noted in dogs of this
report might be explained by several factors. First, nasal
aspergillosis is associated with extensive and irreversible
turbinate destruction, which may have predisposed these
dogs to bacterial rhinitis and sinusitis.10,16 In this study, six
dogs received treatments for persistent signs despite resolu-
tion of the nasal aspergillosis. Three responded to topical
thiamphenicol and acetylcysteine nasal drops, which may
have indicated the presence of bacterial rhinitis. No nasal
cultures were performed in these dogs, however. Second,
rhinosinusitis from aspergillosis is characterized histopatho-
logically by a predominantly lymphoplasmacytic infiltrate
of the nasal mucosa.18 Lymphoplasmacytic rhinitis may
persist even after resolution of the fungal infection and can
cause severe turbinate destruction.19 Given the suspected
immune-mediated origin of lymphoplasmacytic rhinitis,
oral corticosteroids have often been used as treatments.19,21
During the follow-up period, one of the dogs in the present
study was treated with anti-inflammatory doses of methyl-
prednisolone, and the apparent response to treatment may
have been consistent with lymphoplasmacytic rhinitis.
A third possible explanation for the persistence of mild
nasal signs was either ongoing sinonasal aspergillosis (i.e.,
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Figure—Rhinoscopic image (angled dorsally 30˚) of the
right frontal sinus of a 3-year-old, female Labrador retriev-
er, obtained 3 weeks after treatment of sinonasal
aspergillosis with 2% enilconazole infusion administered
via endoscopically placed tubes.
persistent infection) or reinfection (i.e., recurrence). It
seemed unlikely that the presence of nasal signs in half of the
dogs of this study was secondary to persistent nasal
aspergillosis, because there was no evidence of fungal infec-
tion at the time a cure was established. Recurrence was
unlikely given that none of the dogs showed signs of sys-
temic illness or nasal pain, and clinical signs were nonpro-
gressive and mild in nature. However, the absence of fungal
rhinitis was not confirmed by rhinoscopic or microbiological
examination at the time of the owner survey. An attenuated
form of nasal aspergillosis or a form of allergic fungal
sinusitis, as described in humans, may have been present in
these dogs.24
Acute, severe clinical signs of nasal disease recurred in
three dogs, and a second episode of sinonasal aspergillosis
was confirmed rhinoscopically. The three dogs were asymp-
tomatic until relapse. Relapse could be explained by either
persistence of fungal agents or reinfection. Persistence of
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Table
Frequency and Nature of Persistent Clinical Signs in Dogs With Nasal Aspergillosis Treated
With Enilconazole Infusions
All Dogs Treatment Groups
No. of Dogs Group A* Group B†
Clinical Signs (%) No. of Dogs No. of Dogs
No nasal signs 13 (48) 8 5
Nasal signs present 14 (52) 7 7
Frequency
Episodic 5 (19) 3 2
Permanent 9 (33) 4 5
Severity‡
Very mild 3 (11) 1 2
Mild 7 (26) 4 3
Moderate 4 (15) 2 2
Nasal discharge 13 (48)
Serous 3 (11) 1 2
Mucous 3 (11) 1 2
Mucopurulent 7 (26) 5 2
Sneezing 11 (41)
Occasionally 6 (22) 4 2
Regularly (<4 x/d) 3 (11) 0 3
Frequently (>4 x/d) 2 (7) 1 1
Nares 10 (37)
Dryness 6 (22) 4 2
Hyperkeratosis 1 (4) 1 0
Discoloration 3 (11) 1 2
Stertor 3 (11) 1 2
Recurrent disease 3 (11) 1 2
Total dogs 27 (100) 15 12
* Group A=Frontal sinus infusion of 1% enilconazole via blindly placed intranasal tubes
† Group B=Frontal sinus infusion of 2% enilconazole via endoscopically placed intrasinus tubes
‡ See text for definitions
fungi seemed possible in the case that recurred 2 months
after treatment, but it appeared unlikely in the two cases that
were diagnosed 36 months and 23 months later. Whether or
not fungi can persist within sinus mucus without causing
disease is unclear at present.22 Persistence of fungi within
the nasal mucosa may have been possible, despite the
absence of fungal hyphae on histopathological and microbi-
ological examination of tissue biopsies at the time a cure
was established. Current evidence suggests, however, that
canine sinonasal aspergillosis is not associated with signifi-
cant tissue invasion of either mucosa or bone, so the disease
in dogs may be similar to chronic, erosive, noninvasive fun-
gal sinusitis of humans.18,22
Another possible explanation for a second episode of
sinonasal aspergillosis was reinfection. Dogs with sinonasal
aspergillosis are usually considered immunocompetent and
show an active Th-1-dominated immunological response,
which prevents generalized dissemination of the fungal
infection.18 However, some dogs with nasal aspergillosis
have been reported to be immunosuppressed.23 Aspergillus
fumigatus may prevent transformation of B- and T-lympho-
cytes and inhibit mucociliary function of the nasal epithelial
cells in humans in vitro, so it remains unclear whether
immunosuppression is a primary abnormality or is caused
by the disease.24,25 Given that one dog was asymptomatic
for 36 months, it is possible that other dogs in this study
may relapse in the future.
This study had several limitations. Follow-up information
was obtained by telephone conversations with the owners of
the dogs, and the owners may have over- or underreported
clinical signs. In most symptomatic dogs, clinical signs were
not severe enough to justify rhinoscopic reexamination;
however, from a scientific point of view, rhinoscopy would
have been necessary to rule out ongoing fungal disease and
to determine the exact cause of the nasal signs.
Conclusion
Long-term outcomes in 27 dogs after treatment of sinonasal
aspergillosis with topical infusions of 1% and 2% enilcona-
zole were considered good in that 13 of the dogs became
asymptomatic. Symptomatic dogs had generally mild signs
that only occasionally required treatment. Recurrence of
sinonasal aspergillosis was rare (n=3) and may have
occurred from persistence of infection or reinfection.
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